Risk of underperformance and rising costs in subsidiary and affiliate R&D
First written in FY2017. 6 of 11 entries say "Worsened", first in FY2020. Latest entry: FY2026.
OncoTherapy Science moved to the "Worse" side of this theme in 2020.
1 other company's latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「The amount of the negative net worth of the company with negative net worth was ¥2,473 million as of 31 March 2026.」
CPM's negative net worth increased from the ¥2,339 million stated previously as of 31 March 2025 to ¥2,473 million. - 2026-05-08MaterialisedOccurring Fact
「In light of the financial condition of the Company's consolidated subsidiary, the Company recognized a provision for bad debts of ¥134 million related to loans and other receivables.」
In light of the financial condition of the consolidated subsidiary, a provision for bad debts related to loans and other receivables was recognized. The collection risk on loans arising from the subsidiary's financial condition materialized as a loss. - FY2025WorsenedAnnual report
「The amount of the negative net worth of the company with negative net worth was ¥2,339 million as of 31 March 2025.」
CPM's negative net worth increased from the ¥2,235 million stated previously as of 31 March 2024 to ¥2,339 million. - FY2024WorsenedAnnual report
「The amount of the negative net worth of the company with negative net worth was ¥2,235 million as of 31 March 2024.」
CPM's negative net worth increased from the ¥1,832 million stated previously as of 31 March 2023 to ¥2,235 million. - FY2023WorsenedAnnual report
「The amount of the negative net worth of the company with negative net worth was ¥1,832 million as of 31 March 2023.」
CPM's negative net worth increased from the ¥1,784 million stated previously as of 31 March 2022 to ¥1,832 million. - FY2022WorsenedAnnual report
「The amount of the negative net worth of the company with negative net worth was ¥1,784 million as of 31 March 2022.」
CPM's negative net worth increased from ¥948 million as of 31 March 2020 to ¥1,784 million. The parent company also recorded an allowance for doubtful accounts of ¥1,784 million against ¥2,200 million in long-term loans to related companies, including CPM. - FY2020WorsenedAnnual report
「The amount of the negative net worth of the company with negative net worth was ¥948 million as of 31 March 2020.」
CPM's negative net worth of ¥948 million as of 31 March 2020 was explicitly stated. The risk of research and development shortfalls and higher expenses at the subsidiary was presented as a specific financial condition. - FY2018RestatedAnnual report
「There is no guarantee that the research and development activities of these subsidiaries and affiliates can be carried out as planned, and increases in research and development costs associated with business expansion and other factors could adversely affect the Group's performance.」
The company continues to disclose the risk that subsidiaries and affiliates, including CPM, may fail to meet research and development targets and incur higher expenses. - FY2018-Q3RestatedAnnual report
「The Group may establish subsidiaries and affiliates in the future to advance research and development. However, there is no guarantee that the research and development activities of these subsidiaries and affiliates can be carried out as planned, and increases in research and development costs associated with business expansion and other factors could adversely affect the Group's performance.」
The company continues to disclose the risk that subsidiaries and affiliates, including CPM, may fail to meet research and development targets and incur higher research and development expenses. - FY2018-Q2RestatedAnnual report
「The Group may establish subsidiaries and affiliates in the future to advance research and development. However, there is no guarantee that the research and development activities of these subsidiaries and affiliates can be carried out as planned, and increases in research and development costs associated with business expansion and other factors could adversely affect the Group's performance.」
The company continues to disclose the risk that subsidiaries and affiliates, including CPM, may fail to meet research and development targets and incur higher research and development expenses. - FY2017First statedAnnual report
「There is no guarantee that the research and development activities of these subsidiaries and affiliates can be carried out as planned, and increases in research and development costs associated with business expansion and other factors could adversely affect the Group's performance.」
The company has disclosed the risk that research and development conducted through subsidiaries and affiliates may fall short of targets, together with the possibility of higher research and development expenses as a result.